Analysis of the respiratory effects of cannabinoids in rats
- 10 September 2003
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 368 (4) , 301-308
Abstract
The objective of the present study was to evaluate the respiratory effects of cannabinoids and their influence on cardiovascular homeostasis. In spontaneously breathing urethane-anaesthetised rats, intravenous injection of the two synthetic cannabinoid receptor agonists WIN55212-2 and CP55940 strongly and dose-dependently lowered mean arterial pressure, heart rate and the plasma noradrenaline concentration. The cardiovascular depressive effects were associated with a large decrease in respiratory rate, hypoxia, hypercapnia and blood acidosis. All depressor effects of WIN55212-2 were abolished by the selective CB1 cannabinoid receptor antagonist SR141716A. The bradycardia elicited by WIN55212-2 was inhibited by the muscarinic acetylcholine receptor antagonist methylatropine. The natural agonist Δ9-tetrahydrocannabinol also elicited cardiovascular and respiratory depression. In contrast, WIN55212-3, an enantiomer of WIN55212-2 lacking affinity for cannabinoid receptors, had no effect. The cannabinoid-evoked decreases in blood pressure and heart rate were much more pronounced in spontaneously breathing than in artificially ventilated urethane-anaesthetised rats. In contrast, the plasma noradrenaline concentration was lowered equally in both preparations. Our results show that activation of CB1 cannabinoid receptors not only induces cardiovascular depression, but also markedly impairs ventilation. The second major finding of the present study is that the respiratory depression evoked by cannabinoids largely amplifies the cardiovascular depression.Keywords
This publication has 40 references indexed in Scilit:
- Effects of cannabinoids on adrenaline release from adrenal medullary cellsBritish Journal of Pharmacology, 2001
- Effects of imidazoline antihypertensive drugs on sympathetic tone and noradrenaline release in the prefrontal cortexBritish Journal of Pharmacology, 2001
- Cardiovascular effects of endocannabinoids—the plot thickensProstaglandins & Other Lipid Mediators, 2000
- Mechanism of the Hypotensive Action of Anandamide in Anesthetized RatsHypertension, 1996
- Cardiovascular Effects of (-)-11-OH-Δ8-Tetrahydrocannabinol-Dimethylheptyl in RatsJournal of Cardiovascular Pharmacology, 1996
- Regional Cerebral Blood Flow after Marijuana SmokingJournal of Cerebral Blood Flow & Metabolism, 1992
- Cardiovascular effects of Δ9- andΔ9(11)-tetrahydrocannabinol and their interaction with epinephrineLife Sciences, 1987
- Δ9-Tetrahydrocannabinol: Depression of ventilatory regulation; Other respiratory and cardiovascular effectsLife Sciences, 1976
- Combination of Δ9-Tetrahydrocannabinol with Oxymorphone or PentobarbitalAnesthesiology, 1975
- Inhalation, parenteral and oral LD50 values of Δ9-tetrahydrocannabinol in Fischer ratsToxicology and Applied Pharmacology, 1974